CR7091A - RECOMBINANT ANTIBODIES ASSOCIATED WITH GANGLIOSIDS, THEIR USE IN DIAGNOSIS AND TUMORS TREATMENT - Google Patents

RECOMBINANT ANTIBODIES ASSOCIATED WITH GANGLIOSIDS, THEIR USE IN DIAGNOSIS AND TUMORS TREATMENT

Info

Publication number
CR7091A
CR7091A CR7091A CR7091A CR7091A CR 7091 A CR7091 A CR 7091A CR 7091 A CR7091 A CR 7091A CR 7091 A CR7091 A CR 7091A CR 7091 A CR7091 A CR 7091A
Authority
CR
Costa Rica
Prior art keywords
antibodies
murine
diagnosis
frs
produced
Prior art date
Application number
CR7091A
Other languages
Spanish (es)
Inventor
Navarro Lourdes Tatiana Roque
De Acosta Del Río Cristina María Mateo
Valladares Josefa Lombardero
Requena Alejandro López
Original Assignee
Ct De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Inmunología Molecular filed Critical Ct De Inmunología Molecular
Publication of CR7091A publication Critical patent/CR7091A/en

Links

Abstract

La presente invención se relaciona con la obtención de anticuerpos modificados por ingeniería genética a partir del anticuerpo monoclonal murino P3 (AcM P3), producido por el hibridoma depositado según el tratado de Budapest bajo el número ECACC 94113026 y de su anti-idiotipo 1E10 (AcMai 1E10) producido por el hibridoma ECACC 97112901, con el objetivo de lograr anticuerpos con las mismas propiedades de reconocimiento de los originales pero que sean menos inmunogénicos que éstos. Los anticuerpos quiméricos, contienen los dominios variables de la inmunoglobulina murina y las regiones constantes de la inmunoglobulina humana; y los humanizados, además de contener las regiones constantes de la inmunoglobulina humana, son modificados en la región de los marcos (FRs) murinos y en particular en aquellas zonas que pudieran resultar en un sitio antigénico para las células T, por lo que algunas posiciones de los FRS son humanas. Estos anticuerpos pueden ser utilizados en el diagnóstico y la terapia de diferentes tipos de tumores.The present invention relates to obtaining genetically engineered antibodies from the murine monoclonal antibody P3 (AcM P3), produced by the hybridoma deposited according to the Budapest treaty under ECACC number 94113026 and its anti-idiotype 1E10 (AcMai 1E10) produced by the hybridoma ECACC 97112901, with the aim of achieving antibodies with the same recognition properties of the originals but that are less immunogenic than these. The chimeric antibodies contain the variable domains of the murine immunoglobulin and the constant regions of the human immunoglobulin; and the humanized ones, in addition to containing the constant regions of the human immunoglobulin, are modified in the region of the murine frames (FRs) and in particular in those areas that could result in an antigenic site for the T cells, so that some positions of the FRS are human. These antibodies can be used in the diagnosis and therapy of different types of tumors.

CR7091A 2001-04-06 2003-10-01 RECOMBINANT ANTIBODIES ASSOCIATED WITH GANGLIOSIDS, THEIR USE IN DIAGNOSIS AND TUMORS TREATMENT CR7091A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040084 2001-04-06

Publications (1)

Publication Number Publication Date
CR7091A true CR7091A (en) 2004-05-03

Family

ID=51359494

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7091A CR7091A (en) 2001-04-06 2003-10-01 RECOMBINANT ANTIBODIES ASSOCIATED WITH GANGLIOSIDS, THEIR USE IN DIAGNOSIS AND TUMORS TREATMENT

Country Status (1)

Country Link
CR (1) CR7091A (en)

Similar Documents

Publication Publication Date Title
ECSP034788A (en) RECOMBINANT ANTIBODIES ASSOCIATED WITH GANGLIOSIDS USED IN DIAGNOSIS AND TUMORS TREATMENT
MX9201016A (en) CHEMICAL AND HUMANIZED MONOCLONAL ANTIBODIES
NO954626D0 (en) Single-chain anti-EGFR Fvs and anti-EGFR antibodies
DK0586002T3 (en) Monoclonal antibodies that recognize the epidermal growth factor receptor, its cells and methods, and preparations thereof
ATE316137T1 (en) HUMANIZED ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR
RU96115107A (en) "HUMAN" ANTIBODIES AND THEIR USE
DE3485432D1 (en) MONOCLONAL ANTIBODIES WITH SPECIFICITY FOR MEMBRANE-ASSOCIATED ANTIGENS.
RU2011151287A (en) ANTI NOTCH-1 ANTIBODIES
PT90582A (en) ANTI-IDIOTYPE ANTIBODIES TO ANTI-HUMAN HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN
ATE179753T1 (en) MONOCLONAR ANTIBODY AGAINST LPS NUCLEAR
RU2007142005A (en) WISP METHODS AND COMPOSITIONS FOR MODULATION AND DETECTION OF WISP ACTIVITY
CR7091A (en) RECOMBINANT ANTIBODIES ASSOCIATED WITH GANGLIOSIDS, THEIR USE IN DIAGNOSIS AND TUMORS TREATMENT
Maleki et al. Generation and characterization of anti-CD34 monoclonal antibodies that react with hematopoietic stem cells
CU22921A1 (en) CHEMICAL, HUMANIZED ANTIBODIES AND THE SIMPLE CHAIN FV TYPE FRAGMENT RECOGNIZING ANTIGEN C2. ITS USE IN THE DIAGNOSIS AND TREATMENT OF COLORECTURAL TUMORS
KR890016165A (en) Monoclonal Antibodies to Pseudomonas aeruginosa, Methods for Making and Uses thereof
Ezzatifar et al. Development and characterization of monoclonal antibodies against human IgA in Balb/c mice
Kresina et al. An immunoregulatory human monoclonal antibody in Schistosomiasis japonica
CY1107163T1 (en) GANGLIOSITE-CONNECTED RECOVERY ANTIBODIES AND USE THESE IN DIAGNOSIS AND TREATMENT TREATMENT
KR930013103A (en) Tumor-associated monoclonal antibody 88BV59
Wrightham IMMUNOTHERAPEUTIC APPROACHES TO B CELL NEOPLASMS USING MONOCLONAL ANTI-IDIOTYPES AND CELLULAR EFFECTOR MECHANISMS.
RU2000127753A (en) Humanitariannet antibody against human tissue factor (TF) and a method for producing humanized antibodies
IT1254705B (en) New monoclonal antibodies specific for recombinant human ciliar neurotrophic factor (CNTF)
DK182188A (en) HUMANT TUMOR ASSOCIATED ANTIGEN